75
Views
6
CrossRef citations to date
0
Altmetric
Original Research

The Regulating Mechanism of Chrysophanol on Protein Level of CaM-CaMKIV to Protect PC12 Cells Against Aβ25-35-Induced Damage

, , , , , , , , ORCID Icon & ORCID Icon show all
Pages 2715-2723 | Published online: 13 Jul 2020
 

Abstract

Objective

To investigate the neuroprotective effect of chrysophanol (CHR) on PC12 treated with Aβ25-35, and the involved mechanism.

Methods

After the establishment of an AD cell model induced by Aβ25-35, the cell survival rate was detected by MTT, cell apoptosis was assayed by Hoechst 33342 staining, mRNA expressions of calmodulin (CaM), calcium/calmodulin-dependent protein kinase kinase (CaMKK), calcium/calmodulin-dependent protein kinase IV (CaMKIV) and tau (MAPT; commonly known as tau) were determined by qRT-PCR, and protein levels of CaM, CaMKK, CaMKIV, phospho-CaMKIV (p-CaMKIV), tau and phospho-tau (p-tau) were detected by Western blot analysis.

Results

When pretreated with CHR before exposure to Aβ25-35, PC12 cells showed that increased cell viability and reduced apoptosis. The qRT-PCR results indicated that the deposition of Aβ25-35 triggers a decrease in levels of CaM, CaMKK, CaMKIV, and tau in PC12 cells. In addition, Western blot results also suggested that Aβ25-35 decreases the protein expression of CaM, CaMKK, CaMKIV, p-CaMKIV, and the ratio of p-tau to tau in PC12 cells. However, the above effects were significantly alleviated after the treatment of CHR.

Conclusion

CHR plays a neuroprotective role in AD though decreasing the protein level of CaM-CaMKK-CaMKIV and the expression of p-tau downstream.

Acknowledgments

We sincerely thank all the staff who participated in this study. This work was supported by the National Natural Science Foundation of China (Nos. 81574040 and 81873351), the Key Project Foundation of Support Program for the Excellent Young Faculties in Universities of Anhui Province in China (Nos. gxyq ZD2018053 and gxyg2019033), and the Key Natural Research Projects of Anhui University of Traditional Chinese Medicine (No. 2019zrzd01).

Disclosure

The authors declare that they have no conflicts of interest.